

Dear Sirs,

I have just been brought up to speed on the proposals included in FRED 31.

Whilst I agree with the basic principle that when an entity receives goods or other services in exchange for a share-based payment then it should recognise an expense. I must say that I find what is proposed to be over complicated and not very simple!

I am in a small private biotech company and would be unable to tell you what 'fair value' of our shares is. We have agreed a value with the Inland Revenue and the investors in the Company have agreed a value when they invested. No doubt the Black Scholes valuation will come up with a different number. So that makes three valuations all of which will probably be different. Why cant we use some sense in the valuation and use the value the investors used. Why use the Black Scholes method that few people understand?

As for what happens if options are repriced and the charge calculated before the repricing carries on in addition to the charge for the repriced options this does not make sense to me at all. The accounts of companies, for example, who have lost 99% of their share price (not uncommon these days, unfortunately) would look very strange indeed.

The proposals in FRED 31 would also seem to require a fair amount of disclosure. This means that remuneration, derivatives and share based payments disclosures will take up the major part of a company's financial statements. I don't think that this can be right.

From my company's point of view the calculation of a FRED 31 charge would be done at the year end. We would probably have to pay our accountants to do the calculation and they would then come up with a number to put in our accounts and I would have to try and explain it to the Board. There maybe even an effect of companies not issuing shares as a direct result of the proposals.

Regards,

Jim Sutcliffe
Finance Manager
Direct phone - (01223) 765359
Fax - (01223) 333841
www.paradigm-therapeutics.co.uk <<http://www.paradigm-therapeutics.co.uk/>>

Paradigm Therapeutics Limited
Physiological Laboratories
Downing Street
Cambridge
CB2 3EG

Company Registered number - 3585995

No legally binding commitment will be created by this e-mail message. Where Paradigm Therapeutics Limited intends to create a legally binding commitment this will be made through hard copy correspondence or documentation. The information transmitted is intended only for the person or entity to which it is addressed and may contain confidential and/or privileged material. Any reading, review, copying, redistribution, retransmission, dissemination, disclosure or other use of, or taking of any action in reliance upon, this information by persons or entities other than the intended recipient is prohibited. If you are not the intended recipient please contact the sender immediately and delete the material from your computer. E-mail may be susceptible to data corruption, interception, viruses and unauthorised amendment and Paradigm Therapeutics Limited does not accept liability for any such corruption, interception, viruses or amendment or the consequences thereof.

Paradigm Therapeutics Limited is committed to following policies that protect your privacy and comply with current international data protection laws and regulations in respect of personal data.